Biotech Values

[acgood]

TKMR does not stand to receive 5% royalties on TTR02 (and IMO it being a $2b drug is pretty far fetched, at least until we see some clinical data).

From the TKMR-ALNY settlement CC:

So what we’re saying today is, so the historical terms on the licenses which will continue for LNP-based products other than the three that we talked about, we’ve historically characterized as low single digit. And then as part of the restructuring here and in return for the buydown payment, the royalties on ALN-VSP, ALN-PCS and ALN-TTR02 will then be significantly reduced below those figures. There are still royalties on those products, but they will be reduced from that initial starting level. And that’s as precise as we’re being in our public guidance on that, Marko.


And, but, Marko, you could expect that with that type of payment related specifically to the buydown of those royalties, that it was a very significant buydown of those royalties.